Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07180238 · ClinicalTrials.gov registry record
Concept Elicitation and Patient Experience Mapping in SA-AKI
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 28
- Enrollment target
NCT07180238: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07180238 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07180238 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
This is a concept elicitation study on patient's experiences of Sepsis-associated Acute Kidney Injury (SA-AKI)
Primary Outcome
A 60-min qualitative interview will be conducted and transcripts will be coded to assess which signs, symptoms and impacts of SA-AKI have been experienced by the participant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2025-09-30 |
What the finished NCT07180238 record still lists
NCT07180238 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07180238 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07180238 about?
NCT07180238 is a clinical study titled "Concept Elicitation and Patient Experience Mapping in SA-AKI". This is a concept elicitation study on patient's experiences of Sepsis-associated Acute Kidney Injury (SA-AKI)
What is the current status of trial NCT07180238?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2025-05-01. Estimated completion is 2025-09-30.
Who is sponsoring clinical trial NCT07180238?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI